Efficacy of Ascorbic Acid on Reducing the Development of Contrast-Induced Nephropathy

Authors

1 Anesthesiologist, Department of Anesthesiology and Critical Care, Mashhad, IR Iran

2 Associate Professor of Anesthesiology and Critical Care, Cardiac Anesthesia Research Center, Mashhad University of Medical Sciences, Mashhad, IR Iran

Abstract

Introduction: To assess the benefits of prophylactic ascorbic acid to reduce development of contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary interventions (PCIs).

Methods: PubMed was searched with the search strategy of (vitamin C OR ascorbic acid) AND (kidney OR renal) AND (PCI OR percutaneous coronary Intervention OR cardiac OR heart). There was no date and language restriction for the selection of the articles. All the randomized controlled trials (RCTs) which investigated the efficacy of AA on reducing the incidence of CIN were included. Totally 267 articles were found at the initial search; however, only 10 RCTs were eligible to be included. Odds ratio is presented for each of the articles as the effect size.

Conclusions: Controversial findings were reported on the efficacy of AA on reducing the CIN development; due to various limitations of these articles, there is still great debate among the cardiology and radiology communities, which increases the need for further researches.

Keywords

Open Access Policy: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/

References

1.ferences 1. Bagshaw SM, Culleton BF. Contrast-induced nephropathy: epidemiology and prevention. Minerva Cardioangiol. 2006;54(1):109-29. [PubMed: 16467746].
 
2. Mittalhenkle A, Stehman-Breen CO, Shlipak MG, Fried LF, Katz R, Young BA, et al. Cardiovascular risk factors and incident acute renal failure in older adults: the cardiovascular health study. Clin J Am Soc Nephrol. 2008;3(2):450-6. [PubMed: 18256380].
https://doi.org/10.2215/CJN.02610607
PMid:18256380 PMCid:PMC2390946
 
3. Brezis M, Rosen S. Hypoxia of the renal medulla-its implications for disease. N Engl J Med. 1995;332(10):647-55. [PubMed: 7845430].
https://doi.org/10.1056/NEJM199503093321006
PMid:7845430
 
4. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002;162(3):329-36. [PubMed: 11822926].
https://doi.org/10.1001/archinte.162.3.329
PMid:11822926
 
5. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343(3):180-4. [PubMed: 10900277].
https://doi.org/10.1056/NEJM200007203430304
PMid:10900277
 
6. Lloberas N, Torras J, Herrero-Fresneda I, Cruzado JM, Riera M, Hurtado I, et al. Postischemic renal oxidative stress induces inflammatory response through PAF and oxidized phospholipids. Prevention by antioxidant treatment. FASEB J. 2002;16(8):908-10. [PubMed: 12039876].
https://doi.org/10.1096/fj.01-0880fje
PMid:12039876
 
7. Durak I, Ozbek H, Karaayvaz M, Ozturk HS. Cisplatin induces acute renal failure by impairing antioxidant system in guinea pigs: effects of antioxidant supplementation on the cisplatin nephrotoxicity. Drug Chem Toxicol. 2002;25(1):1-8. [PubMed: 11850966].
https://doi.org/10.1081/DCT-100108468
PMid:11850966
 
8. Sai K, Umemura T, Takagi A, Hasegawa R, Kurokawa Y. The protective role of glutathione, cysteine and vitamin C against oxidative DNA damage induced in rat kidney by potassium bromate. Jpn J Cancer Res. 1992;83(1):45-51. [PubMed: 1544873].
https://doi.org/10.1111/j.1349-7006.1992.tb02350.x
PMid:1544873 PMCid:PMC5918653
 
9. Khaledifar A, Momeni A, Ebrahimi A, Kheiri S, Mokhtari A. Comparison of N-acetylcysteine, ascorbic acid, and normal saline effect in prevention of contrast-induced nephropathy. ARYA Atheroscler. 2015;11(4):228-32. [PubMed: 26478730].
 
10. Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004;110(18):2837-42. [PubMed: 15492300].
https://doi.org/10.1161/01.CIR.0000146396.19081.73
PMid:15492300
 
11. Boscheri A, Weinbrenner C, Botzek B, Reynen K, Kuhlisch E, Strasser RH. Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction. Clin Nephrol. 2007;68(5):279-86. [PubMed: 18044259].
https://doi.org/10.5414/CNP68279
PMid:18044259
 
12. Briguori C, Airoldi F, D'Andrea D, Bonizzoni E, Morici N, Focaccio A, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007;115(10):1211-7. [PubMed: 17309916].
https://doi.org/10.1161/CIRCULATIONAHA.106.687152
PMid:17309916
 
13. Jo SH, Koo BK, Park JS, Kang HJ, Kim YJ, Kim HL, et al. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial. Am Heart J. 2009;157(3):576-83. [PubMed: 19249432].
https://doi.org/10.1016/j.ahj.2008.11.010
PMid:19249432
 
14. Alexopoulos E, Spargias K, Kyrzopoulos S, Manginas A, Pavlides G, Voudris V, et al. Contrast-induced acute kidney injury in patients with renal dysfunction undergoing a coronary procedure and receiving non-ionic low-osmolar versus iso-osmolar contrast media. Am J Med Sci. 2010;339(1):25-30. [PubMed: 19996728].
https://doi.org/10.1097/MAJ.0b013e3181c06e70
PMid:19996728
 
15. Zhou L, Chen H. Prevention of contrast-induced nephropathy with ascorbic acid. Intern Med. 2012;51(6):531-5. [PubMed: 22449658].
https://doi.org/10.2169/internalmedicine.51.6260
PMid:22449658
 
16. Dvorsak B, Kanic V, Ekart R, Bevc S, Hojs R. Ascorbic Acid for the prevention of contrast-induced nephropathy after coronary angiography in patients with chronic renal impairment: a randomized controlled trial. Ther Apher Dial. 2013;17(4):384-90. [PubMed: 23931876].
https://doi.org/10.1111/1744-9987.12083
PMid:23931876
 
17. Albabtain MA, Almasood A, Alshurafah H, Alamri H, Tamim H. Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-Induced nephropathy: a prospective randomized study. J Interv Cardiol. 2013;26(1):90-6. [PubMed: 22994682].
https://doi.org/10.1111/j.1540-8183.2012.00767.x
PMid:22994682
 
18. Brueck M, Cengiz H, Hoeltgen R, Wieczorek M, Boedeker RH, Scheibelhut C, et al. Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial. J Invasive Cardiol. 2013;25(6):276-83. [PubMed: 23735352].
Razavi International Journal of Medicine
Volume 5, Issue 1
January 2017

Files

Share

How to cite

Statistics